Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
Radio- plus immuuntherapie lijkt werkzaam bij inoperabel NSCLC
jan 2024 | Longoncologie